Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 4 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 4Recruiting 1

Sponsor Class

INDUSTRY 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 4

Conditions

Non-Muscle Invasive Bladder Neoplasms 3Urinary Bladder Neoplasms 2Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

pembrolizumab 221Carboplatin 214Cisplatin 202Paclitaxel 181Gemcitabine 148Docetaxel 126Capecitabine 113Cyclophosphamide 101Pemetrexed 100Dexamethasone 100Specimen Handling 98Oxaliplatin 96Magnetic Resonance Spectroscopy 96Radiotherapy 92Doxorubicin 91Fluorouracil 88Bevacizumab 84Leucovorin 73Nivolumab 72Rituximab 71Vincristine 67durvalumab 65Lenalidomide 64atezolizumab 61Radiation 61Irinotecan 61Etoposide 60130-nm albumin-bound paclitaxel 58Prednisone 55Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × BCG Vaccine × 1 year × Clear all
NCT05538663 2026-05-05

BRIDGE

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
870 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT03711032 2026-05-01

MK-3475-676

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
1,397 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03528694 2026-04-14

POTOMAC

AstraZeneca

Phase 3 Active not recruiting
1,018 enrolled 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05037279 2026-03-20

EVER

Verity Pharmaceuticals Inc.

Phase 3 Recruiting
540 enrolled
Genitourinary

Urinary Bladder Neoplasms, Recurrence

NCT04165317 2026-01-22

CREST

Pfizer

Phase 3 Active not recruiting
1,068 enrolled 20 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡